Episode
Why Asia is the Emerging Epicenter for Global Biopharmaceutical Progress
- Podcast
- The Bio Report
- Published
- Mar 4, 2026
- Duration seconds
- 2420
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/why-asia-is-the-emerging-epicenter-for-global-biopharmaceutical-progress/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-bio-report-1092382/why-asia-is-the-emerging-epicenter-for-global-biopharmaceutical-progress.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Asia is quickly becoming a powerhouse for biopharma innovation, changing ideas about where breakthrough science and fast, cost-efficient drug development happen. A new McKinsey & Company report shows how countries like China, Japan, and India are each building their own strengths across the drug development continuum. We spoke to Fangning Zhang, a partner in McKinsey’s Shanghai office, about what’s driving this shift, how it could make innovation more affordable, and why treating Asia as optional may mean missing the next wave of global R&D.